ACS
HALO icon

Archford Capital Strategies’s Halozyme HALO Stock Holding History

Archford Capital Strategies’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,736
Closed -$241K – 366
2026
Q1 		$241K Sell
3,736
-420
-10% -$29.6K 0.03% 308
2025
Q4 		$280K Buy
4,156
+91
+2% +$6.12K 0.03% 286
2025
Q3 		$298K Buy
+4,065
New +$270K 0.04% 271

Other funds holding HALO

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MMC
Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.67B AUM 103.47% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
MMA
Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Archford Capital Strategies's HALO Position: Q2 2026 in Review

Archford Capital Strategies sold out of Halozyme (HALO) in Q2 2026, closing a stake of 3,736 shares — an estimated $241K sold.

Archford Capital Strategies first reported a position in HALO in Q3 2025 and held it in 3 quarters. The position peaked at $298K in Q3 2025. 169 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Archford Capital Strategies reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
  • Archford Capital Strategies sold 3,736 Halozyme shares in Q2 2026, an estimated $241K.
  • Archford Capital Strategies first reported a position in Halozyme in Q3 2025 and held it in 3 quarters.
  • Archford Capital Strategies's Halozyme position peaked at $298K in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.